Wedbush Has Positive Forecast for Geron Q2 Earnings

Geron Co. (NASDAQ:GERN - Free Report) - Equities research analysts at Wedbush boosted their Q2 2025 earnings per share (EPS) estimates for Geron in a research note issued to investors on Wednesday, May 7th. Wedbush analyst R. Driscoll now anticipates that the biopharmaceutical company will earn ($0.02) per share for the quarter, up from their previous forecast of ($0.03). The consensus estimate for Geron's current full-year earnings is ($0.25) per share. Wedbush also issued estimates for Geron's Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.08) EPS.

Geron (NASDAQ:GERN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.01. The company had revenue of $39.60 million during the quarter, compared to the consensus estimate of $49.88 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The company's quarterly revenue was up 12927.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.07) EPS.

Several other research firms also recently issued reports on GERN. Barclays reissued an "overweight" rating and issued a $4.00 price target (down previously from $9.00) on shares of Geron in a research report on Thursday, February 27th. B. Riley downgraded shares of Geron from a "buy" rating to a "neutral" rating and cut their price objective for the stock from $3.50 to $2.00 in a report on Thursday, February 27th. Scotiabank downgraded shares of Geron from a "sector outperform" rating to a "sector perform" rating and cut their price objective for the stock from $4.00 to $1.50 in a report on Thursday, May 8th. Needham & Company LLC reaffirmed a "buy" rating and set a $5.00 price objective on shares of Geron in a report on Wednesday, March 12th. Finally, Stifel Nicolaus cut their price objective on shares of Geron from $8.00 to $4.00 and set a "buy" rating on the stock in a report on Thursday, February 27th. One analyst has rated the stock with a sell rating, three have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $5.06.

Geron Stock Up 1.2%

NASDAQ GERN traded up $0.02 during mid-day trading on Monday, hitting $1.23. The company's stock had a trading volume of 1,774,057 shares, compared to its average volume of 11,546,286. The company's 50 day simple moving average is $1.45 and its 200 day simple moving average is $2.66. Geron has a twelve month low of $1.17 and a twelve month high of $5.34. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $780.22 million, a price-to-earnings ratio of -3.83 and a beta of 0.76.

Institutional Investors Weigh In On Geron

Several hedge funds and other institutional investors have recently modified their holdings of GERN. RA Capital Management L.P. increased its position in shares of Geron by 101.2% in the first quarter. RA Capital Management L.P. now owns 60,379,366 shares of the biopharmaceutical company's stock worth $96,003,000 after purchasing an additional 30,369,830 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Geron by 1.8% during the first quarter. Vanguard Group Inc. now owns 34,146,851 shares of the biopharmaceutical company's stock valued at $54,293,000 after acquiring an additional 608,029 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Geron by 20.0% during the fourth quarter. Janus Henderson Group PLC now owns 27,082,461 shares of the biopharmaceutical company's stock valued at $95,769,000 after acquiring an additional 4,516,615 shares in the last quarter. Vestal Point Capital LP raised its holdings in Geron by 100.0% in the first quarter. Vestal Point Capital LP now owns 22,005,340 shares of the biopharmaceutical company's stock worth $34,988,000 after purchasing an additional 11,005,340 shares in the last quarter. Finally, Wellington Management Group LLP raised its holdings in Geron by 6.7% in the fourth quarter. Wellington Management Group LLP now owns 13,510,114 shares of the biopharmaceutical company's stock worth $47,826,000 after purchasing an additional 847,710 shares in the last quarter. 73.71% of the stock is currently owned by institutional investors.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.